Standardized prevalence ratios for chronic hepatitis C virus infection among adult Japanese hemodialysis patients

Journal of Epidemiology

Volumn 20, Issue 1, 2010, Pages 30-39

  Ohsawa, Masaki ^a   Kato, Karen ^a   Itai, Kazuyoshi ^a   Tanno, Kozo ^a   Fujishima, Yosuke ^a   Konda, Ryuichiro ^a   Okayama, Akira ^b   Abe, Koichi ^a   Suzuki, Kazuyuki ^a   Nakamura, Motoyuki ^a   Onoda, Toshiyuki ^a   Kawamura, Kazuko ^c   Sakata, Kiyomi ^a   Akiba, Takashi ^d   Fujioka, Tomoaki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b FUKUJUJI HOSPITAL   (Japan)

^c Iwate Health Service Association   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cross sectional analysis; Hemodialysis; Hepatitis C virus infection; Population based study; Standardized prevalence ratio (SPR)

Indexed keywords

HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; DISEASE TRANSMISSION; EPIDEMIOLOGY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 77649204104     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.JE20090043     Document Type: Article

References (42)

1. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, et al. Prevalence of infected patients and understafng have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004-10.
2. Zampieron A, Jayasekera H, Elseviers M, Lindley E, DeVos JY, Visser R, et al. European study on epidemiology and management of hepatitis C virus (HCV) infection in the haemodialysis population. Part 3: prevalence and incidence. EDTNA ERCA J. 2006;32:42-4.
3. Montella M, Crispo A, Grimaldi M, Angeletti C, Amore A, Ronga D, et al. Prevalence of hepatitis C virus infection in different population groups in southern Italy. Infection. 2005;33:9-12.
4. Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial. 2004;17:310-9.
5. Espinosa M, Martn-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M, et al. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis. 2004;43:685-9.
6. Kumagai J, Komiya Y, Tanaka J, Katayama K, Tatsukawa Y, Yorioka N, et al. Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol. 2005;76:498-502.
7. Bergman S, Accortt N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis. 2005;45:684-9.
8. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335-42.
9. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE.; PHV Study Group. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut. 2002;51:429-33.
10. Shamshirsaz AA, Kamgar M, Bekheirnia MR, Ayazi F, Hashemi SR, Bouzari N, et al. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol. 2004;5:13.
11. Hmaied F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78:185-91.
12. Luengrojanakul P, Vareesangthip K, Chainuvati T, Murata K, Tsuda F, Tokita H, et al. Hepatitis C virus infection in patients with chronic liver disease or chronic renal failure and blood donors in Thailand. J Med Virol. 1994;44:287-92.
13. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19:904-9.
14. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18:1584-93.
15. Washio M, Ikeda M, Okuda S, Makita Y, Hirakata H, Kanai H, et al. Hepatitis C virus antibody among chronic hemodialysis patients and predialysis renal failure patients. J Epidemiol. 1993;3:7-10.
16. Dussol B, Berthezéne P, Brunet P, Roubicek C, Berland Y. Hepatitis C virus infection among chronic dialysis patients in the south of France: a collaborative study. Am J Kidney Dis. 1995;25:399-404.
17. Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Etoh Y, Hayashi J. Conrmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol. 2004;25:584-90.
18. Sypsa V, Psichogiou M, Katsoulidou A, Skoutelis G, Moutas S, Hadjiconstantinou V, et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis. 2005;45:334-43.
19. Alter M, Evatt B, Margolis H, Biswas R, Epstein J, Feinstone S, et al. CDC. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. Morbidity and Mortality Weekly Report. Atlanta, GA: Centers for Disease Control and Prevention, 1991: 1-17.
20. Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000;182:1291-9.
21. Gallego E, López A, Pérez J, Llamas F, Lorenzo I, López E, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006;104:c1-6.
22. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-34.
23. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53:1374-81.
24. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of Anti-Hepatitis C Virus Antibody-Positive Patients on Regular Hemodialysis Therapy. J Am Soc Nephrol. 2000;11:1896-902.
25. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant. 2005;20:1662-9.
26. Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697-703.
27. Ohsawa M, Kato K, Itai K, Onoda T, Konda R, Fujioka T, et al. Cardiovascular Risk Factors in Hemodialysis Patients: Results from Baseline Data of Kaleidoscopic Approaches to Patients with End-stage Renal Disease Study. J Epidemiol. 2005;15:96-105.
28. Altman D. Practical statistics for medical research. London: Chapman & Hall, 1991.
29. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002;36:S3-20.
30. Bouzgarrou N, Fodha I, Othman SB, Achour A, Grattard F, Trabelsi A, et al. Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. J Med Virol. 2005;77:502-8.
31. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24 supple 2:3-8.
32. Washio M. Blood-borne viral infection in hemodialyis units: special reference to hepatitis B virus, hepatitis C virus and human T-lymphotrophic virus type 1. Nippon Koshu Eisei Zasshi. 1998;45:960-7 (in Japanese).
33. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-62.
34. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244(4902):362-4.
35. Izopet J, Sandres-Sauné K, Kamar N, Salama G, Dubois M, Pasquier C, et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol. 2005;77:70-6.
36. Dalrymple LS, Koepsell T, Sampson J, Louie T, Dominitz JA, Young B, et al. Hepatitis C virus infection and the prevalence of renal insufciency. Clin J Am Soc Nephrol. 2007;2:715-21.
37. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439-45.
38. Crook ED, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care. 2005;28:2187-91.
39. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med. 2007;167:1271-6.
40. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-6.
41. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem. 2006;281:18285-95.
42. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386-94.